Buerger K - Search Results

1

Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment.

Bainbridge WA, Berron D, Schütze H, Cardenas-Blanco A, Metzger C, Dobisch L, Bittner D, Glanz W, Spottke A, Rudolph J, Brosseron F, Buerger K, Janowitz D, Fliessbach K, Heneka M, Laske C, Buchmann M, Peters O, Diesing D, Li S, Priller J, Spruth EJ, Altenstein S, Schneider A, Kofler B, Teipel S, Kilimann I, Wiltfang J, Bartels C, Wolfsgruber S, Wagner M, Jessen F, Baker CI, Düzel E. Bainbridge WA, et al. Among authors: buerger k. Alzheimers Dement (Amst). 2019 Sep 5;11:610-618. doi: 10.1016/j.dadm.2019.07.005. eCollection 2019 Dec. Alzheimers Dement (Amst). 2019. PMID: 31517023 Free PMC article.

2

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H. Buerger K, et al. Neurology. 2002 Aug 27;59(4):627-9. doi: 10.1212/wnl.59.4.627. Neurology. 2002. PMID: 12196665

3

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Hampel H, et al. Among authors: buerger k. Mol Psychiatry. 2004 Jul;9(7):705-10. doi: 10.1038/sj.mp.4001473. Mol Psychiatry. 2004. PMID: 14699432

4

Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment.

Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman D, Du Y, Hampel H. Buerger K, et al. Neurosci Lett. 2005 Dec 31;391(1-2):48-50. doi: 10.1016/j.neulet.2005.08.030. Epub 2005 Sep 13. Neurosci Lett. 2005. PMID: 16165272 Clinical Trial.

5

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.

Buerger K, Otto M, Teipel SJ, Zinkowski R, Blennow K, DeBernardis J, Kerkman D, Schröder J, Schönknecht P, Cepek L, McCulloch C, Möller HJ, Wiltfang J, Kretzschmar H, Hampel H. Buerger K, et al. Neurobiol Aging. 2006 Jan;27(1):10-5. doi: 10.1016/j.neurobiolaging.2004.12.003. Neurobiol Aging. 2006. PMID: 16298235 Clinical Trial.

6

Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.

Omerovic M, Hampel H, Teipel SJ, Buerger K. Omerovic M, et al. Among authors: buerger k. World J Biol Psychiatry. 2008;9(1):69-75. doi: 10.1080/15622970701568412. World J Biol Psychiatry. 2008. PMID: 17886162 Review.

7

Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.

Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H. Buerger K, et al. J Clin Psychiatry. 2011 Apr;72(4):556-63. doi: 10.4088/JCP.09m05872oli. Epub 2010 Nov 2. J Clin Psychiatry. 2011. PMID: 21208578

8

Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.

Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, Möller HJ, Hampel H, Buerger K. Buschert VC, et al. Among authors: buerger k. J Alzheimers Dis. 2011;25(4):679-94. doi: 10.3233/JAD-2011-100999. J Alzheimers Dis. 2011. PMID: 21483095 Clinical Trial.

9

Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.

Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K. Förster S, et al. Among authors: buerger k. J Alzheimers Dis. 2011;25(4):695-706. doi: 10.3233/JAD-2011-100996. J Alzheimers Dis. 2011. PMID: 21498904 Clinical Trial.

10

Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.

Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, Teipel SJ. Likitjaroen Y, et al. Among authors: buerger k. Eur Arch Psychiatry Clin Neurosci. 2012 Jun;262(4):341-50. doi: 10.1007/s00406-011-0234-2. Epub 2011 Aug 5. Eur Arch Psychiatry Clin Neurosci. 2012. PMID: 21818628 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters